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Background-—Treatments for patients with myocardial ischemia in the absence of angiographic obstructive coronary artery
disease are limited. In these patients, particularly those with diabetes mellitus, diffuse coronary atherosclerosis and microvascular
dysfunction is a common phenotype and may be accompanied by diastolic dysfunction. Our primary aim was to determine whether
ranolazine would quantitatively improve exercise-stimulated myocardial blood ﬂow and cardiac function in symptomatic diabetic
patients without obstructive coronary artery disease.
Methods and Results-—We conducted a double-blinded crossover trial with 1:1 random allocation to the order of ranolazine and
placebo. At baseline and after each 4-week treatment arm, left ventricular myocardial blood ﬂow and coronary ﬂow reserve (CFR;
primary end point) were measured at rest and after supine bicycle exercise using 13N-ammonia myocardial perfusion positron
emission tomography. Resting echocardiography was also performed. Multilevel mixed-effects linear regression was used to
determine treatment effects. Thirty-ﬁve patients met criteria for inclusion. Ranolazine did not signiﬁcantly alter rest or postexercise
left ventricular myocardial blood ﬂow or CFR. However, patients with lower baseline CFR were more likely to experience
improvement in CFR with ranolazine (r=0.401, P=0.02) than with placebo (r=0.188, P=0.28). In addition, ranolazine was
associated with an improvement in E/septal e0 (P=0.001) and E/lateral e0 (P=0.01).
Conclusions-—In symptomatic diabetic patients without obstructive coronary artery disease, ranolazine did not change exercise-
stimulated myocardial blood ﬂow or CFR but did modestly improve diastolic function. Patients with more severe baseline
impairment in CFR may derive more beneﬁt from ranolazine.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identiﬁer: NCT01754259. ( J Am Heart Assoc. 2017;6:
e005027. DOI: 10.1161/JAHA.116.005027.)
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M yocardial ischemia in the absence of angiographicobstructive coronary artery disease (CAD) poses a
signiﬁcant management challenge for patients and providers.
This clinical scenario is frequently encountered in clinical
practice,1 particularly in women,2 and is associated with
increased risk of adverse cardiovascular events and disabil-
ity.3,4 Diffuse coronary atherosclerosis and microvascular
dysfunction is a common phenotype in these patients and
may be accompanied by diastolic dysfunction.5 These asso-
ciations are especially evident among high-risk cohorts,
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including patients with diabetes mellitus6 and patients with
chronic renal impairment.7,8 In diabetics, diffuse coronary
vascular dysfunction precedes overt atherosclerosis,9 and the
absence of traditionally deﬁned myocardial ischemia does not
necessarily correspond to lower risk.10 Importantly, current
treatment strategies for obstructive epicardial CAD, such as
percutaneous angioplasty and stenting, are ineffective for
diffuse CAD and microvascular dysfunction.
Ranolazine is a novel anti-anginal agent11,12 that, under
ischemic conditions, inhibits the late sodium current in
cardiomyocytes and thereby decreases sodium and calcium
overload. Excess intracellular calcium may impair myocyte
relaxation and contribute to ventricular diastolic stiffness,
which in turn affects myocardial contractility and perfu-
sion.13,14 Although ranolazine’s mechanism of action is
thought to be mediated in part by increased myocardial
blood ﬂow (MBF),15 prior studies utilizing vasodilator stress
protocols have shown conﬂicting data regarding this hypoth-
esis16,17 and no prior study has tested it with an exercise
stress protocol.
Accordingly, we conducted a randomized, double-blind,
placebo-controlled, 2-way crossover trial in symptomatic
diabetic patients without obstructive CAD to test the hypoth-
esis that treatment with ranolazine would quantitatively
improve exercise-related MBF and cardiac function.
Methods
Study Design
The study was a randomized, double-blinded, crossover trial
with 1:1 random allocation to the order of ranolazine and
placebo. The washout period between treatment arms was
3 days, representing 10 times the terminal half-life of
ranolazine (7 hours). Figure 1 shows the study ﬂow chart. At
each of the 3 study visits, patients underwent a blood draw, a
12-lead ECG, a standard resting transthoracic echocardio-
gram, and dynamic supine bicycle exercise stress-rest
myocardial perfusion positron emission tomography (PET).
Serum biomarkers included N-terminal pro-B-type natriuretic
peptide and high-sensitivity C-reactive protein. For safety
monitoring, plasma glucose, hemoglobin A1c, lipid panels,
complete blood count, and renal and liver function panels
were also obtained at each visit.
Patient Population
Brigham & Women’s Hospital provider patient panels were
screened to identify patients with diabetes mellitus, stable
angina and/or exertional dyspnea, and exercise tolerance of
at least 3 metabolic equivalents on a treadmill or bicycle
exercise tolerance test. Patients with obstructive CAD
Figure 1. Patient enrollment, screening, randomization, and completion ﬂow diagram.
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(deﬁned as ≥50% luminal stenosis) on clinically indicated
invasive coronary angiography or coronary computed
tomography (CT) angiography within 1 year prior to study
screening were excluded, as were those with a history of
cardiomyopathy (left ventricular ejection fraction <40%),
moderate–severe valvular heart disease, uncontrolled hyper-
tension (systolic blood pressure >180 mm Hg), renal
impairment (estimated glomerular ﬁltration rate <50 mL/
min per 1.73 m2), and/or a contraindication to ranolazine.
Patients already taking ranolazine for clinical indications
were also excluded. Qualifying patients were contacted by
phone to request voluntary participation in the study.
Consistent with prior ranolazine trials,16,18,19 patient symp-
toms at baseline were conﬁrmed using the Seattle Angina
Questionnaire (ie, score <100)20 and the Rose Dyspnea
Scale (ie, score >0).21 If patients had not undergone
invasive or CT coronary angiography within 1 year, we
performed screening coronary CT angiography and excluded
any patients with ≥50% luminal stenosis from further study
participation. The study was approved by the Partners
Healthcare Institutional Review Board and registered at
ClinicalTrials.gov (NCT 01754259). All study patients gave
written informed consent.
Randomization
The order of ranolazine and placebo exposure was randomly
assigned in a 1:1 ratio by the Investigational Drug Service at
Brigham & Women’s Hospital. During the 28-day treatment
periods, ranolazine (Gilead Sciences, Foster City, CA) and
matching placebo were administered as 500 mg by mouth
twice daily for 1 week and increased to 1000 mg by mouth
twice daily for 3 weeks, as tolerated. Minimum ranolazine
dosing and duration of treatment periods were based on prior
data that monotherapy with 500 mg twice daily for 1 week is
sufﬁcient to increase exercise tolerance in patients with
chronic angina.22 Treatment compliance was measured by
pill count. Patients and study investigators were blinded
to treatments and treatment order throughout the study
protocol.
Assessment of Myocardial Blood Flow and
Coronary Flow Reserve
MBF was measured at rest and in response to supine bicycle
exercise using 13N-ammonia as a ﬂow tracer. Patients were
studied using a whole body PET-CT scanner (Discovery RX or
STE LightSpeed 64; GE Healthcare, Milwaukee, WI) after an
overnight fast. Patients refrained from b-blockers, calcium
channel blockers, and nitroglycerin for 24 hours before their
scans. After transmission CT imaging and beginning with the
intravenous bolus administration of 13N-ammonia (15 mCi)
at rest, list mode images were acquired for 20 minutes. After
radioactive decay of the rest radioactive dose, the patient was
positioned for supine bicycle exercise on the PET table, just
outside the imaging gantry. Symptom-limited supine bicycle
exercise stress using a standardized ramp protocol was then
performed. At peak stress, exercise was stopped and patients
were immediately repositioned in the PET gantry using skin
landmarks, at which point a second dose of 13N-ammonia
(15 mCi) was administered followed by list mode imaging
for 20 minutes. The time between peak exercise stress and
13N-ammonia injection was 20 s. A second CT transmission
scan was obtained immediately after completion of the stress
imaging, and used for attenuation correction of the stress
images. The average radiation exposure per complete PET/CT
study was 2.8 mSv. Heart rate, blood pressure, and 12-lead
ECG were recorded at baseline and every minute during and
after exercise stress. An identical stress protocol and
workload was used for stress PET scans after each treatment
arm.
Assessment of the global extent and severity of regional
perfusion abnormalities was assessed by quantifying the total
perfusion deﬁcit at rest, after stress, and their difference
using commercially available software (QPS; Cedars Sinai, Los
Angeles, CA). Patients with a total perfusion deﬁcit during
stress >8.8% (corresponding to a summed stress score >6
and suggestive of clinically signiﬁcant obstructive CAD) on the
baseline study were excluded from further study participation.
Rest and postexercise left ventricular ejection fraction were
calculated from gated myocardial perfusion images using
commercially available software (Corridor4DM; INVIA Medical
Imaging Solutions, Ann Arbor, MI).
Absolute left ventricular (LV) MBF (in mL/g per minute)
was computed from the dynamic rest and exercise-stress
imaging series using the same commercially available
software and previously validated methods.23 Automated
regions of interest were used to generate blood pool (arterial
input function) and tissue time–activity curves. Regional and
global LV rest and exercise MBF were calculated by ﬁtting the
13N-ammonia time–activity curves to a 2-compartment tracer
kinetic model as described previously.24,25 Per-patient global
coronary ﬂow reserve (CFR) was calculated as the ratio of
absolute MBF at stress over rest for the entire left ventricle.
Quantitation of MBF was performed by 2 operators blinded to
the patient, treatment, and treatment order. The intraclass
correlation coefﬁcient for MBF and CFR among these readers
was 0.94 (95% CI 0.88–0.98), indicating excellent repro-
ducibility.23 To account for differences in resting cardiac
workload, which can affect global rest LV MBF, “corrected”
CFR was calculated: corrected CFR=peak global LV MBF/
[(rest MBF/rest rate-pressure product)910 000].
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Assessment of Diastolic and Systolic Left
Ventricular Function
Resting echocardiograms were acquired by an experienced
sonographer using a Philip iE33 machine (Philips Corporation,
Andover, MA) and included standard 2-dimensional views
recommended by the American Society of Echocardiogra-
phy.26 Acquired images were digitally stored for quantitative
measurements performed by 4 expert echocardiographers
blinded to the patient, treatment, and treatment order. LV end-
diastolic and end-systolic volumes (used to calculate left
ventricular ejection fraction), left atrial volume, septal and
lateral peak early diastolic tissue velocity (e0), septal and lateral
peak systolic tissue velocity (s0), and mitral inﬂow velocity (E)
were all measured in accordance with American Society of
Echocardiography guidelines.27,28 Each measurement was
performed in triplicate by the same echocardiographer for all
study patients. Intraclass correlation coefﬁcients for all
echocardiographic measurements, performed on 15 randomly
selected study echocardiograms, are provided in Table S1.
Statistical Analysis
We calculated that a sample size of 35 evaluable patients was
needed to provide 80% power to detect a 20% relative
improvement in immediate postexercise global LV CFR
(primary end point) from baseline. Percent improvement from
baseline in all other quantitative serum biomarker and
echocardiographic measures were secondary end points. All
patients who received at least 1 dose of each intervention and
had a PET interpretable for CFR at all 3 study visits were
included in the efﬁcacy analysis. For the primary end point,
and all secondary end points, individual multilevel mixed-
effects linear regression models were used to determine
independent treatment effects. In each model, percent
change from baseline was used as the outcome variable
and ﬁxed effects included treatment phase (ie, ranolazine or
placebo), treatment order (ie, ranolazine-ﬁrst or placebo-ﬁrst),
and average daily dose. A per-patient random effect was
included to account for any within-patient correlation of
repeated measures. All statistical tests were performed with
2-sided a=0.05 and were performed using Stata software
version 13.1 (StataCorp, College Station, TX).
Study Oversight
The study was investigator initiated and funded by Gilead
Sciences, Inc, the American College of Cardiology, and the
National Heart, Lung, and Blood Institute at the National
Institutes of Health. The authors are solely responsible for the
study design and conduct, all statistical analyses, drafting and
editing of the manuscript, and its ﬁnal contents. Study
characteristics conform to the Consolidated Standards of
Reporting Trials (CONSORT) guidelines for reporting random-
ized clinical trials. An independent Data and Safety Monitoring
Board monitored patient safety.
Results
Cohort Characteristics at Baseline
From July 2013 through April 2015, 47 patients who met the
inclusion and exclusion criteria were enrolled. There was 1
screen failure (obstructive CAD identiﬁed on coronary CT
angiography) and 6 patients withdrew consent before ran-
domization (Figure 1). Of the remaining 40 randomized
patients, 3 dropped out while receiving ranolazine, 1 dropped
out while receiving placebo, and 1 was excluded for PET
images that were not interpretable for CFR. Accordingly, 35
patients were included in the primary analysis.
The baseline demographic and clinical characteristics of
the study cohort are shown in Table 1. The median age was
64 years (interquartile interval [IQI]: 61–67) and 49% were
women. The median baseline hemoglobin A1c was 7.4% (IQI:
6.8–8.2). Of the 19 patients (54%) with known CAD, 15 had
undergone coronary revascularization (43% of the overall
cohort). With respect to baseline antianginal medication use
in the study cohort, 20% of patients were on long-acting
nitrates, 63% were on b-blockers, and 26% were on calcium
channel-blockers.
Hemodynamic Parameters at Rest and During
Exercise
Compared with placebo, ranolazine treatment did not change
resting heart rate, systolic blood pressure, mean arterial blood
pressure, or rate–pressure product. Likewise, ranolazine
treatment did not change immediate postexercise heart rate,
systolic blood pressure, mean arterial blood pressure, or rate–
pressure product. Cardiac workload achieved with exercise,
assessed by both total metabolic equivalents and peak:rest
rate–pressure product, was not signiﬁcantly different between
ranolazine and placebo treatments. A summary of all rest and
exercise hemodynamic parameters is provided in Table S2.
Importantly, our immediate postexercise hemodynamic mea-
surements represented a drop-off of 10% or less from those at
peak exercise, as shown in Table S3.
Effect of Ranolazine on Myocardial Blood Flow,
Coronary Flow Reserve, Diastolic Function, and
Serum Biomarkers
In multivariable analysis accounting for treatment phase,
treatment order, and average daily dose, ranolazine treatment
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did not signiﬁcantly alter rest or immediate postexercise global
LV MBF, CFR, or corrected CFR relative to placebo (Table 2).
However, in exploratory secondary analyses, we found a
signiﬁcant inverse correlation whereby patients with lower
baseline corrected CFR were more likely to experience
improvement following treatment with ranolazine (r=0.401,
P=0.02). A similar statistically signiﬁcant negative correlation
was not seen following treatment with placebo (r=0.188,
P=0.28) (Figure 2), though the difference between the corre-
lation coefﬁcients for ranolazine and placebo did not reach
statistical signiﬁcance (2-tailed P=0.35 utilizing the above
correlation r values and n=35 for each treatment group).
In multivariable analysis accounting for treatment phase,
treatment order, and average daily dose, ranolazine was
associated with an improvement in E/septal e0 (P=0.001) and
E/lateral e0 (P=0.01) relative to placebo (Table 2). In
exploratory secondary analyses, we did not ﬁnd a signiﬁcant
inverse correlation between baseline E/e0 (septal or lateral)
and its improvement following treatment with ranolazine.
Relative to placebo, ranolazine treatment did not signiﬁcantly
alter other echocardiographic parameters of resting systolic
and diastolic cardiac performance, nor serum high-sensitivity
C-reactive protein or serum N-terminal pro-B-type natriuretic
peptide (Table 2).
Compliance and Safety
The median daily dose of ranolazine was 1750 mg (IQI: 1722–
2000) and the median daily dose of placebo was 1750 mg
(IQI: 1467–2000). There were no serious adverse events
during the ranolazine or washout periods. One serious
adverse event occurred during the placebo period (fall
complicated by nonfatal intracerebral hemorrhage). Nonseri-
ous adverse events during the ranolazine period occurred in
12 patients (nausea and dizziness [9], hypoglycemia [1], renal
abnormality [1], transaminitis [1]). Among the 12 patients with
nonserious adverse events during ranolazine treatment, 3
patients dropped out of the study and in the remaining 9
patients dose reduction to 500 mg twice daily resulted in
resolution of adverse effects. Nonserious adverse events
during the placebo period occurred in 2 patients (hematuria
[1], chest pain requiring evaluation [1]). Finally, nonserious
adverse events occurred in 2 patients during follow-up after
protocol completion (chest pain requiring evaluation [1],
nephrolithiasis [1]). Complete follow-up at 2 weeks after
protocol completion was obtained in 100% of patients.
Discussion
In our cohort of symptomatic patients with diabetes mellitus,
we found that treatment with ranolazine resulted in a modest
but signiﬁcant improvement in diastolic function, without a
change in exercise-stimulated MBF or CFR compared to
placebo. In our exploratory secondary analyses, however, we
found a signiﬁcant inverse correlation whereby patients
with lower baseline corrected CFR measurements were more
likely to experience improvement following treatment with
ranolazine.
Table 1. Study Cohort Baseline Demographic and Clinical
Characteristics
All Study Participants
(n=35)
Age, y 64 [61, 67]
Female 17 (49%)
Body mass index, kg/m2 31 [27, 36]
Cardiovascular risk factors
Hypertension 30 (86%)
Dyslipidemia 33 (94%)
Family history of CAD 11 (31%)
Chronic kidney disease 3 (9%)
Current tobacco use 2 (6%)
Cardiovascular history
Known CAD 19 (54%)
Myocardial infarction 6 (17%)
Coronary revascularization 15 (43%)
Percutaneous coronary intervention 8 (23%)
Coronary artery bypass grafting 10 (29%)
Stroke 2 (6%)
Peripheral vascular disease 3 (9%)
Medications
Insulin 13 (37%)
Aspirin 28 (80%)
b-Blocker 22 (63%)
Calcium channel blocker 9 (26%)
ACE inhibitor or ARB 27 (77%)
Statin 34 (97%)
Diuretic 15 (43%)
Nitrate 7 (20%)
Symptoms
Angina and dyspnea on exertion 24 (69%)
Angina only 8 (23%)
Dyspnea on exertion only 3 (9%)
Serum labs
Creatinine, mg/dL 0.9 [0.7, 1.1]
Continuous variables represented as median [interquartile interval] and dichotomous
variables as n (%). Symptoms were assessed by the Seattle Angina Questionnaire and the
Rose Dyspnea Scale. ACE indicates angiotensin-converting enzyme; ARB, angiotensin II
receptor blocker; CAD, coronary artery disease.
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Our primary observation that ranolazine does not improve
CFR in symptomatic diabetic patients without obstructive
CAD is concordant with the ﬁndings of Villano et al,29 who
found that ranolazine did not have an effect on coronary
microvascular function in patients with microvascular angina
pectoris. However, our data conﬂict with those of Tagliamonte
et al,17 who found that ranolazine improved CFR in patients
with symptoms of myocardial ischemia in the absence of
obstructive CAD. There are several possible explanations for
this discrepancy. First, less than 25% of the Tagliamonte
cohort had diabetes mellitus, in whom hyperglycemia and
hyperinsulinemia may trigger distinct pathophysiologic mech-
anisms to produce microvascular ischemia compared with
other disease processes.30,31 Second, we induced coronary
hyperemia with exercise while Tagliamonte et al did so with
dipyridamole. Coronary hyperemia elicited with vasodilators
such as dipyridamole or adenosine uncouples blood ﬂow from
cardiac work and reﬂects predominantly endothelial-indepen-
dent vasodilation. Exercise, on the other hand, triggers a more
complex interplay between metabolic demand, coronary
hemodynamics, and vasodilator response. Finally, Taglia-
monte et al measured CFR with echocardiography only in
the left anterior descending coronary artery, whereas we
measured CFR with PET over the entire LV.
Our ﬁnding that ranolazine modestly improves LV ﬁlling
pressures in symptomatic diabetic patients without obstruc-
tive CAD is a novel ﬁnding. To date, the only trials examining
the effect of ranolazine on echocardiographic measures of
diastolic function have been in animal models or patients with
heart failure with preserved ejection fraction. The data in
those studies are equivocal regarding the improvement of
echocardiographic measures of diastolic function with
ranolazine.32,33
Our exploratory analyses demonstrating a potential gradi-
ent phenomenon governing the effects of ranolazine on MBF
are consistent with recently published data by Bairey-Merz
et al, who also showed that patients with lower baseline CFR
had signiﬁcantly greater improvement in midventricular
Table 2. Treatment Effect of Ranolazine on MBF, CFR, Diastolic Function, and Serum Biomarkers
Baseline Median [IQI] Ranolazine % Change Placebo % Change Treatment Effect*
MBF outcomes
Rest global MBF, mL/g per minute 0.85 [0.68, 0.95] 7 [12, 11] 1 [15, 7] P=0.23
Immediate postexercise global MBF, mL/g per minute 1.48 [1.23, 1.65] 3 [14, 10] 2 [15, 3] P=0.19
CFR 1.80 [1.43, 2.07] 0 [10, 14] 2 [14, 16] P=0.60
Corrected CFR† 1.50 [1.35, 1.95] 4 [14, 17] 2 [17, 21] P=0.84
Rest echocardiography outcomes
Lateral e0, m/s (n=28) 0.09 [0.08, 0.10] 4 [8, 13] 1 [12, 10] P=0.31
Septal e0, m/s (n=28) 0.07 [0.06, 0.08] 0 [8, 12] 7 [18, 10] P=0.05
E/lateral e0 (n=28) 8.6 [6.6, 10.3] 3 [19, 14] 4 [13, 28] P=0.01
E/septal e0 (n=26) 10.2 [8.6, 11.2] 4 [16, 12] 8 [0, 22] P=0.001
Left atrial volume, mL (n=26) 26 [22, 38] 4 [6, 37] 11 [19, 48] P=0.21
LVEDV, mL (n=28) 77 [63, 99] 1 [10, 7] 2 [15, 8] P=0.04
LVESV, mL (n=28) 33 [25, 42] 5 [11, 27] 2 [22, 27] P=0.20
LV ejection fraction, % (n=28) 58 [56, 63] 1 [6, 4] 2 [10, 10] P=0.75
Lateral s0, m/s (n=27) 0.08 [0.07, 0.09] 0 [4, 14] 5 [15, 6] P=0.51
Septal s0, m/s (n=28) 0.07 [0.07, 0.08] 0 [11, 7] 7 [16, 5] P=0.07
Serum biomarker outcomes
Glucose, % 139 [103, 190] 6 [12, 40] 11 [6, 41] P=0.57
Hemoglobin A1c, mg/dL 7.4 [6.8, 8.2] 1 [5, 4] 2 [6, 2] P=0.96
High-sensitivity CRP, mg/L (n=31) 2.2 [1.1, 5.9] 8 [36, 33] 0 [28, 25] P=0.36
NT-proBNP, pg/mL (n=34) 67 [30, 113] 10 [36, 28] 4 [24, 61] P=0.31
CFR indicates coronary ﬂow reserve; CRP, C-reactive protein; HR, heart rate; IQI, interquartile interval, LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic
volume; MBF, myocardial blood ﬂow; NT-proBNP, N-terminal of prohormone brain natriuretic peptide; SBP, systolic blood pressure.
*Treatment effect P value based on mixed linear regression model with % change from baseline as the outcome variable and ﬁxed variables of treatment phase (ranolazine vs placebo),
treatment order, and per-patient average daily ranolazine and placebo dose. A per-patient random effect was also included to account for any within-patient correlation of repeated
measures.
†Corrected CFR calculation: peak global LV MBF/(rest MBF/(rest HR9rest SBP)910 000).
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myocardial perfusion reserve index with ranolazine.34 Prior
histopathologic studies in diabetic patients have shown
phenotypic heterogeneity with respect to coronary arteriolar
thickening, perivascular accumulations of connective tissue,
and myocardial stiffening.35,36 Patients with these phenotypic
features may have more severe impairment of CFR than those
with isolated endothelial dysfunction from hyperglycemia,
inﬂammation, and oxidative stress.30,37,38 It may be this more
severe phenotype that derives more clinical beneﬁt from
treatment with ranolazine.
Finally, our protocol coupling supine bicycle exercise stress
with dynamic PET imaging to quantify absolute MBF imaging is
relatively novel. Krivokapich et al showed the feasibility of
quantifying MBF from dynamic PET images acquired during
peak exercise in normal volunteers.39 However, the relatively
longer gantry length of modern PET-CT scanners (compared to
older standalone PET scanners) physically precludes supine
exercise during image acquisition. Our exercise stress proto-
col was designed to minimize the delay between peak
exercise and initiation of dynamic PET image acquisition to
20 s. Indeed, our baseline absolute immediate postexercise
global MBF measurements (Table 2) are very similar to those
measured by Krivokapich et al.39 Accordingly, we believe this
protocol may be attractive to clinical trialists seeking an
accurate, precise, and reproducible noninvasive measurement
of postexercise absolute MBF.
While our trial had several strengths, including a crossover
trial design, a disease-focused cohort comprising both men
and women, use of an exercise-based stress protocol, and
well-validated imaging outcome measures, we acknowledge
its limitations as well. The ﬁrst is our relatively small cohort
size of 35 patients, which limited generalizability and our
statistical power for detecting differences in our secondary
analyses and in any potential cohort subgroups. A second
important limitation is that our mechanistic trial was not
designed to assess clinical outcomes. Accordingly, it is
possible that some of the nonsigniﬁcant improvements we
saw with ranolazine compared to placebo (eg, immediate
postexercise MBF, serum high-sensitivity C-reactive protein,
serum N-terminal pro-B-type natriuretic peptide) could con-
tribute to a meaningful reduction in adverse clinical outcomes
in a larger population of similar patients. Finally, our
experimental design allowed for inclusion of patients with
nonobstructive epicardial CAD and patients with mild stress
perfusion defects (summed stress score <6). While this was
done to acknowledge the signiﬁcant real-world challenge of
identifying symptomatic diabetic patients without any epicar-
dial coronary artery disease (ie, “pure” microvascular disease),
doing so may have created a bias toward our negative CFR
results. Speciﬁcally, patients in our cohort with impaired CFR
more prominently inﬂuenced by diffuse “nonobstructive”
epicardial atherosclerosis and/or small myocardial scarring
may have been less likely to respond to any potential
beneﬁcial effects of ranolazine on microvascular function.
In conclusion, in symptomatic diabetic patients without
obstructive CAD, we found that treatment with ranolazine did
not change exercise-stimulated MBF or CFR but did result in a
modest but signiﬁcant improvement in diastolic function. In
addition, our exploratory analyses suggest that diabetic
patients with more severely impaired coronary ﬂow reserve
may derive more beneﬁt from ranolazine than their counter-
parts with less severe phenotypes.
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SUPPLEMENTAL MATERIAL 
 
Table S1. Intraobserver and interobserver intraclass correlations for echocardiographic 
measurements. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Two-way mixed-effects model with 2 raters and 15 targets. 
 Intraclass Correlation 
Echocardiographic 
Measurement 
Intraobserver 
(n=15) 
Interobserver 
(n=15) 
Lateral E’, m/s 0.96 0.96 
Septal E’, m/s 0.94 0.49 
E/lateral e’ 0.99 0.97 
E/septal e’ 0.99 0.99 
Left atrial volume, mL 0.49 0.90 
LVEDV, mL 0.94 0.94 
LVESV, mL 0.87 0.86 
LV ejection fraction, % 0.42 0.63 
Lateral S’, m/s 0.93 0.83 
Septal S’, m/s 0.47 0.16 
Table S2. Change in rest and exercise hemodynamics, and cardiac workload achieved with 
exercise after treatment with placebo and ranolazine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Treatment effect p value based on mixed linear regression model with % change from baseline as the outcome 
variable and fixed variables of treatment phase (ranolazine vs. placebo), treatment order, and per-patient average 
daily ranolazine and placebo dose. A per-patient random effect was also included to account for any within-patient 
correlation of repeated measures. BP, blood pressure; IQI, interquartile interval, MAP, mean arterial pressure; 
METS, metabolic equivalents. 
 
Baseline 
[IQI] 
Ranolazine 
% Change 
[IQI] 
Placebo 
% Change 
[IQI] 
Treatment 
Effect* 
Rest Hemodynamics 
Rest heart rate (bpm) 
69 
[61,77] 
0 
[-8,5] 
0 
[-11,6] 
p=0.59 
Rest systolic BP (mm Hg) 
128 
[116,137] 
-4 
[-8,8] 
-1 
[-10,12] 
p=0.77 
Rest MAP (mm Hg) 
87 
[80,92] 
-3 
[-10,7] 
0 
[-10,11] 
p=0.60 
Rest rate-pressure product 
8806 
[7442,10488] 
0 
[-9, 13] 
-2 
[-11,11] 
p=0.97 
Peak Exercise Hemodynamics 
Peak heart rate (bpm) 
126 
[118,136] 
-4 
[-7,0] 
-2 
[-7,2] 
p=0.47 
Peak systolic BP (mm Hg) 
174 
[164,186] 
-3 
[-8,0] 
-5 
[-11,3] 
p=0.97 
Peak MAP (mm Hg) 
109 
[103,121] 
-3 
[-8,6] 
-1 
[-8,5] 
p=0.81 
Peak rate-pressure product 
22304 
[20160,25944] 
-6 
[-14,-2] 
-7 
[-17,2] 
p=0.51 
Cardiac Workload Achieved With Exercise 
METS 
5.0 
[4.0,5.9] 
0 
[0,0] 
0 
[0,0] 
p=0.60 
Peak:rest rate-pressure 
product 
2.6 
[2.2,2.9] 
-8 
[-16,7] 
-7 
[-18,15] 
p=0.74 
Table S3. Peak exercise vs. immediate post-peak hemodynamics for all PET studies. 
 
 Peak Exercise [IQI] Immediate Post-Peak [IQI] 
Heart rate (bpm) 126 [113,136] 113 [100,126] 
Systolic BP (mm Hg) 172 [160,184] 173 [153,185] 
MAP (mm Hg) 109 [101,118] 107 [97,117] 
Rate-pressure product 21360 [18984,23944] 19379 [15714,22684] 
 
BP, blood pressure; IQI, interquartile interval; MAP, mean arterial pressure. 
 
